A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS (Brain Tumors)
Study of PF-07799544 in Patients with Solid Brain Tumors
Sponsor: Pfizer Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU5536
U.S. Govt. ID: NCT05538130
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to learn about the safety (the impact of the study drug on your body) and the effects of study drug PF-07799544 for specific types of cancer on the body and to find the best dose for treating certain cancers. For BRAF (B-raf proto-oncogene serine/threonine kinase) mutated solid tumors, PF-07799544 may be combined with encorafenib, also known as BRAFTOVI (an FDA-approved cancer medication). The study drug PF-07799544 is an investigational drug because it is not FDA-approved for use in this country. The study drug encorafenib is approved in this country and is available by prescription for approved indications, however, it is considered investigational in this study because it is not being used according to its FDA-approved label. Different doses of the study drug, PF-07799544, will be given to several study participants. The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. The doses will continue to increase for every group of study participants until side effects occur that require the dose to be lowered.
Investigator
Fabio Iwamoto, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Are you willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162